A listing of human tumor antigens recognized by T cells

Cancer Immunology, Immunotherapy

Volumn 50, Issue 1, 2001, Pages 3-15

  Renkvist, N ^a   Castelli, C ^a   Robbins, P F ^a   Parmiani, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antigens; Epitopes; T cells; Tumor

Indexed keywords

GENE PRODUCT; HLA ANTIGEN; HYBRID PROTEIN; TUMOR ANTIGEN;

ANTIGEN FUNCTION; ANTIGEN RECOGNITION; CLASSIFICATION; HUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TISSUE DISTRIBUTION; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; EPITOPES; HUMANS; T-LYMPHOCYTES;

EID: 0035095532     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000169     Document Type: Review

References (147)

1. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1
2. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients
3. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line
4. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene
5. Specific human cellular immunity to bcr-abl oncogene-derived peptides
6. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
7. Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells
8. Human tumor antigens recognized by T lymphocytes
9. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma
10. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
11. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
12. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein
13. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes
14. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes
15. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens
16. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1
17. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes
18. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
19. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene
20. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells
21. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
22. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
23. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
24. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
25. A family of rapidly evolving genes from the sex reversal critical region in Xp21
26. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis
27. Structure, chromosomal localization, and expression of 12 genes of the MAGE family
28. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients
29. Sequence and expression pattern of the human MAGE2 gene
30. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter
31. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin
32. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens
33. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes
34. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
35. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3
36. The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes
37. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes
38. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells
39. A hs70-2 mutation recognized by CTL on a human renal cell carcinoma
40. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
41. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma
42. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs
43. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes
44. An antigen recognized by autologous CTLs on a human bladder carcinoma
45. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene
46. CT10: A new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis
47. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12
48. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3
49. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells
50. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene
51. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7
52. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma
53. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
54. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
55. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
56. Analysis of HLA antigens on germ cells in human semen
57. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
58. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
59. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
60. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
61. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
62. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles
63. Human tumor antigens recognized by T-cells
64. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer
65. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells
66. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
67. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes
68. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development
69. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase
70. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient
71. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes
72. LAGE-1, a new gene with tumor specificity
73. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
74. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells
75. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: Four new members of the MAGE family with tumor-specific expression
76. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage
77. Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins
78. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
79. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
80. Identification on a human sarcoma of two new genes with tumor-specific expression
81. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
82. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma
83. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
84. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence
85. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL
86. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2
87. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia
88. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide
89. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes
90. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
91. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12
92. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
93. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors
94. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes
95. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
96. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells
97. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes
98. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
99. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes
100. Immune recognition of cancer - Tumor antigens
101. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
102. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ
103. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
104. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells
105. Expression of cancer-testis antigens in lung cancer: Definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9
106. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1
107. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes
108. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100
109. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes
110. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes
111. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24
112. Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes
113. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family
114. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells
115. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
116. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct
117. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene
118. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
119. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
120. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
121. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
122. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells
123. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
124. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription
125. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
126. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
127. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601
128. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product
129. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes
130. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
131. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
132. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen
133. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33
134. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
135. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen
136. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells
137. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
138. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
139. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients
140. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner
141. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia
142. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia
143. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein
144. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
145. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
146. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resultin from a somatic point mutation
147. A MAGE-6-encoded peptide is recognized by expanded lymphocyte infiltrating a spontaneously regressing human primary melanoma lesion